Basilea Pharmaceutica AG (BPMUF)
USD 47.5
(0.0%)
USD 47.5
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 111.09 Million CHF | -24.78% |
| 2022 | 147.68 Million CHF | 56.19% |
| 2021 | 94.55 Million CHF | -60.69% |
| 2020 | 240.56 Million CHF | 21.66% |
| 2019 | 197.74 Million CHF | 0.38% |
| 2018 | 196.98 Million CHF | 0.39% |
| 2017 | 196.22 Million CHF | 0.63% |
| 2016 | 195 Million CHF | 0.0% |
| 2015 | 195 Million CHF | 0.0% |
| 2014 | - CHF | 0.0% |
| 2013 | - CHF | 0.0% |
| 2012 | - CHF | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 95.68 Million CHF | 0.0% |
| 2023 Q1 | 129.79 Million CHF | -12.11% |
| 2023 Q2 | 129.79 Million CHF | 0.0% |
| 2023 Q3 | 111.09 Million CHF | -14.41% |
| 2023 Q4 | 111.09 Million CHF | 0.0% |
| 2023 FY | 111.09 Million CHF | -24.78% |
| 2022 Q1 | 111.98 Million CHF | 18.45% |
| 2022 Q3 | 147.68 Million CHF | 55.83% |
| 2022 Q4 | 147.68 Million CHF | 0.0% |
| 2022 FY | 147.68 Million CHF | 56.19% |
| 2022 Q2 | 94.77 Million CHF | -15.38% |
| 2021 Q3 | 94.55 Million CHF | -58.51% |
| 2021 Q1 | 227.95 Million CHF | -4.89% |
| 2021 FY | 94.55 Million CHF | -60.69% |
| 2021 Q2 | 227.86 Million CHF | -0.04% |
| 2021 Q4 | 94.54 Million CHF | -0.01% |
| 2020 Q3 | 240.56 Million CHF | 21.42% |
| 2020 Q4 | 239.66 Million CHF | -0.37% |
| 2020 Q1 | 199.11 Million CHF | 0.7% |
| 2020 FY | 240.56 Million CHF | 21.66% |
| 2020 Q2 | 198.11 Million CHF | -0.5% |
| 2019 Q2 | 197.35 Million CHF | 0.0% |
| 2019 Q4 | 197.74 Million CHF | -0.28% |
| 2019 Q1 | 197.35 Million CHF | 0.19% |
| 2019 Q3 | 198.28 Million CHF | 0.47% |
| 2019 FY | 197.74 Million CHF | 0.38% |
| 2018 FY | 196.98 Million CHF | 0.39% |
| 2018 Q4 | 196.98 Million CHF | 0.0% |
| 2018 Q3 | 196.98 Million CHF | 0.19% |
| 2018 Q2 | 196.6 Million CHF | 0.0% |
| 2018 Q1 | 196.6 Million CHF | 0.19% |
| 2017 Q2 | 195.84 Million CHF | 0.0% |
| 2017 FY | 196.22 Million CHF | 0.63% |
| 2017 Q4 | 196.22 Million CHF | 0.0% |
| 2017 Q3 | 196.22 Million CHF | 0.2% |
| 2017 Q1 | 195.84 Million CHF | 0.19% |
| 2016 Q3 | 195.46 Million CHF | 0.2% |
| 2016 FY | 195 Million CHF | 0.0% |
| 2016 Q2 | 195.08 Million CHF | 0.0% |
| 2016 Q1 | 195.08 Million CHF | 0.19% |
| 2016 Q4 | 195.46 Million CHF | 0.0% |
| 2015 FY | 195 Million CHF | 0.0% |
| 2015 Q4 | 194.7 Million CHF | 0.0% |
| 2015 Q3 | 194.7 Million CHF | 0.0% |
| 2015 Q1 | - CHF | 0.0% |
| 2015 Q2 | - CHF | 0.0% |
| 2014 Q1 | - CHF | 0.0% |
| 2014 Q3 | - CHF | 0.0% |
| 2014 Q2 | - CHF | 0.0% |
| 2014 FY | - CHF | 0.0% |
| 2014 Q4 | - CHF | 0.0% |
| 2013 FY | - CHF | 0.0% |
| 2013 Q1 | - CHF | 0.0% |
| 2013 Q2 | - CHF | 0.0% |
| 2013 Q3 | - CHF | 0.0% |
| 2013 Q4 | - CHF | 0.0% |
| 2012 Q4 | - CHF | 0.0% |
| 2012 Q3 | - CHF | 0.0% |
| 2012 FY | - CHF | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -67553.847% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -8943.84% |
| Evofem Biosciences, Inc. | 8000.00 USD | -1388537.5% |
| GB Sciences, Inc. | 322 Thousand USD | -34400.311% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -64778.234% |
| Zenith Capital Corp. | 4456.00 USD | -2492965.53% |
| Agentix Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -4926.742% |
| CSL Limited | 11.23 Billion USD | 99.012% |
| CytoDyn Inc. | 141 Thousand USD | -78687.943% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -446.923% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -189339.31% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -74151.741% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -6228.244% |
| SQZ Biotechnologies Company | 20.9 Million USD | -431.307% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -2015339.042% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Mesoblast Limited | 100.29 Million USD | -10.764% |
| Marizyme, Inc. | 667.12 Thousand USD | -16552.102% |
| Genus plc | 228.2 Million USD | 51.319% |
| Pharming Group N.V. | 166.1 Million USD | 33.12% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -7818.477% |
| IMV Inc. | 27.39 Million USD | -305.463% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -1947.202% |
| MultiCell Technologies, Inc. | 36.43 USD | -304943627.697% |
| ONE Bio Corp. | 592.19 Thousand USD | -18659.097% |
| RVL Pharmaceuticals plc | 55.61 Million USD | -99.761% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -4890.611% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -439012.218% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -5751.613% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| Enzolytics Inc. | - USD | -Infinity% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | -623.531% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 287.12 Million USD | 61.31% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -87856.644% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -48349.787% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -1244.276% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -19931.194% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -41720.92% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -73960.667% |
| Resverlogix Corp. | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -48265.413% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -10440783.459% |
| LadRx Corporation | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -74151.741% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 445 Thousand USD | -24864.27% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -138763.75% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -1320.608% |
| SYBLEU INC | 300 Thousand USD | -36930.333% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -30001.965% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -1263.08% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -24208.753% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -9468.562% |
| PureTech Health plc | 18.25 Million USD | -508.718% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -73960.667% |
| IXICO plc | 275 Thousand USD | -40296.727% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -838.348% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -322.255% |
| CSL Limited | 11.23 Billion USD | 99.012% |
| Cellectis S.A. | 36.21 Million USD | -206.787% |